Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods: Data were analyzed from 95 patients with aquapori...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2021-11-01
|
| Серія: | Frontiers in Neurology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fneur.2021.696387/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|